Antigen binding molecule formats

Patent metadata

Field	Value
Publication number	US-12331109-B2
Application number	US-202418640981-A
Country	US
Kind code	B2
Filing date	Apr 19, 2024
Priority date	Aug 8, 2019
Publication date	Jun 17, 2025
Grant date	Jun 17, 2025

Abstract

Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

First claim

What is claimed is:

1. An antigen-binding molecule comprising:
(a) a first polypeptide chain comprising, in an N- to C-terminal orientation:
(i) a first Fc domain;
(ii) a first linker;
(iii) a first VH domain; and
(iv) a first CH1 domain;

(b) a second polypeptide chain comprising, in an N- to C-terminal orientation:
(i) a second Fc domain;
(ii) a second linker;
(iii) a second VH domain; and
(iv) a second CH1 domain;

(c) a third polypeptide chain comprising a universal light chain, wherein the third polypeptide is associated with the first VH domain and the first CH1 domain to form a first Fab; and
(d) a fourth polypeptide chain comprising a universal light chain, wherein the fourth polypeptide is associated with the second VH domain and the second CH1 domain to form a second Fab.

2. The antigen-binding molecule of claim 1 , wherein the first linker and the second linker each comprise a multimer of G n S or SG n .

3. The antigen-binding molecule of claim 2 , wherein n is an integer from 1 to 7.

4. The antigen-binding molecule of claim 1 , wherein the first linker and the second linker each comprise (G 4 S) n .

5. The antigen-binding molecule of claim 4 , wherein n is an integer from 1 to 6.

6. The antigen-binding molecule of claim 1 , wherein the first linker and the second linker are each 5 amino acids to 60 amino acids in length.

7. The antigen-binding molecule of claim 1 , wherein the first linker and the second linker are each 5 amino acids to 20 amino acids in length.

8. The antigen-binding molecule of claim 1 , wherein the first linker and the second linker are each 10 amino acids to 60 amino acids in length.

9. The antigen-binding molecule of claim 1 , wherein the first linker and the second linker are each 10 amino acids to 20 amino acids in length.

10. The antigen-binding molecule of claim 1 , wherein the first linker and the second linker are each 25 to 35 amino acids in length.

11. The antigen-binding molecule of claim 1 , wherein the first polypeptide chain comprises a first hinge sequence N-terminal to the first Fc domain, and the second polypeptide chain comprises a second hinge sequence N-terminal to the second Fc domain.

12. The antigen-binding molecule of claim 11 , wherein the first polypeptide chain comprises a third hinge sequence between the first Fc domain and the first linker, and the second polypeptide chain comprises a fourth hinge sequence between the second Fc domain and the second linker.

13. The antigen-binding molecule of claim 11 , wherein (1) the first hinge sequence comprises the amino acid sequence of SEQ ID NO: 1 and (2) the second hinge sequence comprises the amino acid sequence of SEQ ID NO:1.

14. The antigen-binding molecule of claim 11 , wherein (1) the first hinge sequence comprises the amino acid sequence of SEQ ID NO:2 and (2) the second hinge sequence comprises the amino acid sequence of SEQ ID NO:2.

15. The antigen-binding molecule of claim 1 , wherein the first Fc domain is an IgG Fc domain.

16. The antigen-binding molecule of claim 15 , wherein the first Fc domain is an IgG4 Fc domain.

17. The antigen-binding molecule of claim 15 , wherein the first Fc domain comprises the amino acid sequence of residues 99-326 of SEQ ID NO:31.

18. The antigen-binding molecule of claim 15 , wherein the first Fc domain is an IgG1 Fc domain.

19. The antigen-binding molecule of claim 1 , wherein the second Fc domain is an IgG domain.

20. The antigen-binding molecule of claim 19 , wherein the second Fc domain is an IgG4 Fc domain.

21. The antigen-binding molecule of claim 19 , wherein the second Fc domain comprises the amino acid sequence of residues 99-326 of SEQ ID NO:31.

22. The antigen-binding molecule of claim 17 , wherein the second Fc domain comprises the amino acid sequence of residues 99-326 of SEQ ID NO:31.

23. The antigen-binding molecule of claim 19 , wherein the second Fc domain is an IgG1 Fc domain.

Assignees

• Regeneron Pharma

Inventors

• Zhang Tong
• Pyles Erica
• Rosconi Michael
• Liu Nina
• Patel Supriya
• Smith Eric
• Murphy Andrew
• Lin Chia-Yang
• Davis Samuel

Classifications

• C07K2317/53

  Hinge · CPC title

• C07K2317/522

  CH1 domain · CPC title

• C07K16/30

  from tumour cells · CPC title

• C07K16/244 Primary

  Interleukins [IL] · CPC title

• C07K16/46 Primary

  Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) · CPC title